Book contents
- Frontmatter
- Contents
- List of contributors
- Preface
- Part I Introduction: definition and classification of the human herpesviruses
- Part II Basic virology and viral gene effects on host cell functions: alphaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: betaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: gammaherpesviruses
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HSV-1 and HSV-2
- Part III Pathogenesis, clinical disease, host response, and epidemiology: VZU
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HCMV
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HHV- 6A, 6B, and 7
- Part III Pathogenesis, clinical disease, host response, and epidemiology: gammaherpesviruses
- Part IV Non-human primate herpesviruses
- Part V Subversion of adaptive immunity
- Part VI Antiviral therapy
- Part VII Vaccines and immunothgerapy
- 69 Herpes simplex vaccines
- 70 Varicella-zoster vaccine
- 71 Human cytomegalovirus vaccines
- 72 Epstein–Barr virus vaccines
- 73 DNA vaccines for humanherpesviruses
- 74 Adoptive immunotherapy for herpesviruses
- 75 Immunotherapy of HSV infections – antibody delivery
- Part VIII Herpes as therapeutic agents
- Index
- Plate section
- References
69 - Herpes simplex vaccines
from Part VII - Vaccines and immunothgerapy
Published online by Cambridge University Press: 24 December 2009
Book contents
- Frontmatter
- Contents
- List of contributors
- Preface
- Part I Introduction: definition and classification of the human herpesviruses
- Part II Basic virology and viral gene effects on host cell functions: alphaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: betaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: gammaherpesviruses
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HSV-1 and HSV-2
- Part III Pathogenesis, clinical disease, host response, and epidemiology: VZU
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HCMV
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HHV- 6A, 6B, and 7
- Part III Pathogenesis, clinical disease, host response, and epidemiology: gammaherpesviruses
- Part IV Non-human primate herpesviruses
- Part V Subversion of adaptive immunity
- Part VI Antiviral therapy
- Part VII Vaccines and immunothgerapy
- 69 Herpes simplex vaccines
- 70 Varicella-zoster vaccine
- 71 Human cytomegalovirus vaccines
- 72 Epstein–Barr virus vaccines
- 73 DNA vaccines for humanherpesviruses
- 74 Adoptive immunotherapy for herpesviruses
- 75 Immunotherapy of HSV infections – antibody delivery
- Part VIII Herpes as therapeutic agents
- Index
- Plate section
- References
Summary
Introduction
Genital herpes, caused by both herpes simplex virus (HSV) types 1 and 2, can result in painful vesicular and ulcerative lesions on the genitalia and the genital tract, and may cause both urologic and neurologic problems. Following primary infection, HSV establishes a latent infection in the local ganglia and can reactivate on multiple occasions with manifestations ranging from asymptomatic viral shedding to painful recurrences of genital or orofacial lesions (Whitley, 2001). HSV-2 is the predominant etiologic agent of genital herpes and data from the second and third National Health and Nutrition Examination Surveys, spanning 1976 to 1994, demonstrated that the prevalence of HSV-2 infection increased by 30% since the late 1970's with the highest rates in teenagers and young adults (Fleming et al., 1997). It is estimated that more than 1.6 million individuals are infected annually with HSV-2 in the USA (Armstrong et al., 2001). From the perspective of vaccine development, however, genital herpes caused by HSV-1 cannot be overlooked. Although genital herpes caused by HSV-1 is generally less severe than HSV-2, HSV-1 is ubiquitous, infects a larger portion of the population than HSV-2, and the percentage of HSV-1 positive cultures isolated from individuals presenting with genital herpes appears to be increasing (Ribes et al., 2001).
In addition to the pain and potential complications (e.g. psychological distress), that genital herpes causes in the infected individual, it is also responsible for increasing the risk of sexual transmission of HIV (Holmberg et al., 1988).
- Type
- Chapter
- Information
- Human HerpesvirusesBiology, Therapy, and Immunoprophylaxis, pp. 1253 - 1261Publisher: Cambridge University PressPrint publication year: 2007
References
, , et al. (2001). Incidence of herpes simplex virus type 2 infection in the United States.'Am. J. Epidemiol., 153(9), 912–920.CrossRefGoogle Scholar
and (1997). Herpes simplex virus Type 2 – a persistent problem. N. Engl. J. Med., 337, 1158–1159.CrossRefGoogle ScholarPubMed
and (2001). Herpes simplex inhibits the capacity of lymphoblastoid B cell lines to stimulate CD4+ T cells. J. Immunol., 166(10): 6242–6249.CrossRefGoogle ScholarPubMed
Ben, , et al. (2003). Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J. Virol., 77(17), 9463–9473.Google Scholar
, , et al. (2003). Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J. Infect. Dis., 187(4), 542–549.CrossRefGoogle ScholarPubMed
, , et al. (1997). A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J. Infect. Dis., 175(1), 16–25.CrossRefGoogle ScholarPubMed
, , et al. (1997). The acquisition of herpes simplex virus during pregnancy. N. Engl. J. Med., 337(8), 509–515.CrossRefGoogle ScholarPubMed
, , , , , and (2003). Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. J. Am. Med. Assoc., 289(2), 203–209.CrossRefGoogle ScholarPubMed
(1993). Current status of HSV vaccine development. In The Human Herpesviruses. R. J. W. a. C. L. B. Roizman. New York, Raven Press, pp. 367–379.Google Scholar
, , et al. (1992). Phase 1 trial of R7020: a live attenuated recombinant herpes simplex (HSV) candidate vaccine. ICAAC Washington DC (Abstract).
, , , and (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science, 250(4985), 1262–1266.CrossRefGoogle ScholarPubMed
, , et al. (1999). Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. J. Am. Med. Assoc., 282(4), 331–340.CrossRefGoogle ScholarPubMed
Da , , , and (1997). Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology, 232(1), 1–12.CrossRefGoogle Scholar
Da , , and (1999). Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc. Natl Acad. Sci. USA, 96(12), 6994–6998.CrossRefGoogle ScholarPubMed
, , , , , and (1994). Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J. Virol., 68(2), 927–932.Google ScholarPubMed
, , et al. (1997). Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med., 337(16), 1105–1111.CrossRefGoogle ScholarPubMed
, , and (2001). Oral transgene vaccination mediated by attenuated Salmonellae is an effective method to prevent Herpes simplex virus-2 induced disease in mice. Vaccine, 19(13–14), 1772–1782.Google Scholar
(2003). Papillomavirus vaccines in clinical trials. Lancet. Infect. Dis., 3(8), 469–475.CrossRefGoogle ScholarPubMed
, , , , , and (2002). Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. J. Virol., 76(13), 6568–6576.CrossRefGoogle ScholarPubMed
, , and (2002). Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK. Vaccine, 20(21–22), 2796–2807.CrossRefGoogle ScholarPubMed
, , and (2003). Viral inhibition of MHC class II antigen presentation. Trends Immunol., 24(5), 278–285.CrossRefGoogle ScholarPubMed
, , , , and (1995). Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J. Virol., 69(12), 8109–8113.Google ScholarPubMed
, , et al. (1988). Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. J. Am. Med. Assoc., 259(7), 1048–1050.CrossRefGoogle ScholarPubMed
and (1998). Herpesvirus evasion of the immune system. Curr. Top. Microbiol. Immunol., 232, 149–177.Google ScholarPubMed
, , et al. (2001). Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics, 108(2), 223–229.CrossRefGoogle ScholarPubMed
, , et al. (2000). Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. J. Infect. Dis., 181(1), 335–339.CrossRefGoogle ScholarPubMed
, , et al. (2002). A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med., 347(21), 1645–1651.CrossRefGoogle ScholarPubMed
, , et al. (1995). A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. Ann. Intern. Med., 122(12), 889–898.CrossRefGoogle Scholar
, , , , and (1999). A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N. Engl. J. Med., 341(19), 1432–1438.CrossRefGoogle ScholarPubMed
(2002). Counteraction of interferon-induced antiviral responses by herpes simplex viruses. Curr. Top. Microbiol. Immunol., 269, 171–185.Google ScholarPubMed
, , and (2001). Viral immune evasion strategies and the underlying cell biology. Semin. Immunol., 13(1), 1–9.CrossRefGoogle ScholarPubMed
Mc, , et al. (1994). Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J. Infect. Dis., 170(5), 1100–1109.Google Scholar
, , and (1988). In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J. Infect. Dis., 158(3), 602–614.CrossRefGoogle ScholarPubMed
, , , and (1990). In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis., 162(2), 313–321.CrossRefGoogle Scholar
, , , , , and (2001). A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J. Virol., 75(11), 5189–5196.CrossRefGoogle ScholarPubMed
, , et al. (2000). Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J. Virol., 74(17), 7745–7754.CrossRefGoogle ScholarPubMed
, , , , and (1999). Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. Vaccine, 17(18), 2229–2236.CrossRefGoogle ScholarPubMed
, , et al. (2005). Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine, 23, 5424–5431.CrossRefGoogle ScholarPubMed
, Mc, et al. (2002). Disabled infectious single cycle-herpes simplex virus (DISC-HSV) as a vector for immunogene therapy of cancer. Curr. Opin. Mol. Ther., 4(1), 49–53.Google Scholar
, , , and (2001). Six-year study of the incidence of herpes in genital and nongenital cultures in a central Kentucky medical center patient population. J. Clin. Microbiol., 39(9), 3321–3325.CrossRefGoogle Scholar
, , and (2000). Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs. J. Infect. Dis., 181(4), 1240–1248.CrossRefGoogle ScholarPubMed
Spear, P., (1985). Glycoproteins specified by Herpes simplex viruses. In , ed. The Herpesviruses. New York: Plenum, 3, 315–356.Google Scholar
, , et al. (1998). Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J. Infect. Dis., 177(5), 1143–1154.CrossRefGoogle ScholarPubMed
, , (1999). New developments in the epidemiology, natural history and management of genital herpes. Antiviral Res., 42(1), 1–14.CrossRefGoogle ScholarPubMed
, , et al. (2002). Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med., 347(21), 1652–1661.CrossRefGoogle ScholarPubMed
, , , , and (2000). Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs. J. Infect. Dis., 182(5), 1304–1310.CrossRefGoogle ScholarPubMed
, , and , eds. (2000). Vaccines for the 21st Century. A Tool for Decision Making. Washington, DC: National Academy Press.Google Scholar
, , et al. (1997). Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J. Infect. Dis., 176(5), 1129–1134.CrossRefGoogle Scholar
and (2002). Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther., 9(12), 967–978.CrossRefGoogle ScholarPubMed
, , , , and (1995). Virologic characteristics of subclinical and symptomatic genital herpes infections. N. Engl. J. Med., 333(12), 770–775.CrossRefGoogle ScholarPubMed
Whitley, R. J. (2001). Herpes simplex viruses. In and , eds. Fields Virology, 4th edn. Lippincott, Williams & Wilkins, 2.
, , , , and (1993). Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J. Clin. Invest., 91(6), 2837–2843.CrossRefGoogle ScholarPubMed
, , et al. (2002). Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988–1994. J. Infect. Dis., 185(8), 1019–1024.CrossRefGoogle ScholarPubMed
- 6
- Cited by